Bayer’s head of Pharmaceuticals talks to Euractiv about US tariffs, expresses scepticism over CMA, and how the discussion on RDP should be focused on increasing it for incentivising competitiveness.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback